vTv Therapeutics Q4 EPS $(0.58) Beats $(1.17) Estimate
vTv Therapeutics, Inc. Class A
vTv Therapeutics, Inc. Class A VTVT | 0.00 |
vTv Therapeutics (NASDAQ:
VTVT) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(1.17) by 50.21 percent. This is a 5.45 percent decrease over losses of $(0.55) per share from the same period last year.
